Screener
BridgeBio Pharma BBIO Noncash interest expense on deferred royalty obligations
Noncash interest expense on deferred royalty obligations at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept bbio:NoncashInterestExpenseOnDeferredRoyaltyObligations.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Other income (expense), net: | ||
| Interest income | 6,246 | 5,385 |
| Interest expense | (12,942) | (18,121) |
| Noncash interest expense on deferred royalty obligations (1) | (39,873) | (24,020) |
| Loss on extinguishment of debt | — | (21,155) |
| Net loss from equity method investments | (18,283) | (15,556) |
| Other income, net | 4,253 | 8,231 |
| Total other expense, net | (60,599) | (65,236) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's noncash interest expense on deferred royalty obligations?
- BridgeBio Pharma (BBIO) reported noncash interest expense on deferred royalty obligations of $39.87M in Q1 2026.
- How has BridgeBio Pharma's noncash interest expense on deferred royalty obligations changed year-over-year?
- BridgeBio Pharma's noncash interest expense on deferred royalty obligations increased by 66.0% year-over-year, from $24.02M to $39.87M.
- What does noncash interest expense on deferred royalty obligations mean?
- This represents the non-cash interest expense accrued on obligations tied to future royalty payments. It reflects the cost of financing arrangements where the company receives upfront capital in exchange for future revenue streams.
Ask your AI about BridgeBio Pharma's noncash interest expense on deferred royalty obligations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude